PuSH - Publikationsserver des Helmholtz Zentrums München

Tawk, B.* ; Halec, G.* ; Rein, K.* ; Schwager, C.* ; Knoll, M.* ; Wirkner, U.* ; Held, T.* ; Weykamp, F.* ; Liermann, J.* ; Hoerner-Rieber, J.* ; Kurth, I.* ; Balermpas, P.* ; Rödel, C.* ; Fleischmann, M.* ; Linge, A.* ; Löck, S.* ; Lohaus, F.* ; Tinhofer, I.* ; Krause, M.* ; Stuschke, M.* ; Grosu, A.L.* ; Schäfer, H.* ; Zips, D.* ; Combs, S.E.* ; Belka, C. ; Stenzinger, A.* ; Herold-Mende, C.* ; Baumann, M.* ; Schirmacher, P.* ; Debus, J.* ; Abdollahi, A.*

A tumor DNA-Methylome derived signature of Hypoxia Identifies HPV-negative head and neck cancer patients at risk for distant metastasis after postoperative radiochemotherapy (PORT-C).

Radiother. Oncol. 217:111433 (2026)
Verlagsversion Forschungsdaten DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
BACKGROUND AND PURPOSE: Tumor hypoxia is a predictive biomarker of treatment resistance in patients with head and neck squamous cell carcinoma (HNSCC). We previously reported the discovery of a tumor DNA methylation signature of hypoxia (Hypoxia-M), identifying HNSCC patients at risk for local recurrence (LR), all event progression, and death after primary radiochemotherapy (RCHT). We further validate Hypoxia-M in an independent cohort of HNSCC patients who underwent surgical resection followed by postoperative radiochemotherapy (PORT-C) METHODS: Hypoxia-M was validated in HPV-negative HNSCC patients (n = 134) homogeneously treated with PORT-C in the frame of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG) multicenter biomarker trial. DNA methylation was profiled using Illumina450K technology. The performance of Hypoxia-M was integrated with previously reported biomarkers, including gene expression signatures (GES) of hypoxia, a methylome-based HPV-Independent Classifier of disease Recurrence (HICR), and immune cell score using immunohistochemistry (CD3/CD8/PD-L1/PD1). RESULTS: Hypoxia-M was independently prognostic for overall survival (OS, HR = 2.34, p = 0.03) and distant metastasis (DM, HR = 4.3, p = 0.001), but not for LR after PORT-C. Hypoxia-M remained significant after adjusting for patientś age, gender, smoking status, tumor stage, and high-risk features (ECE&/R1 resection). Hypoxia-M status was inversely associated with CD8 T-cell infiltration. Patient stratification improved by integrating previously reported biomarkers, with Hypoxia-M demonstrating independent prognostic performance. CONCLUSIONS: The prognostic utility of Hypoxia-M was validated in an independent cohort. Our results highlighted a difference in recurrence patterns of hypoxic tumors treated in the primary setting (local recurrence) versus postoperatively (distant metastasis) and the utility of Hypoxia-M for identifying the main pattern of recurrence.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Good Prognosis Subgroups; Squamous-cell Carcinoma; Locally Advanced Head; Marker Expression; Radiation; Multicenter; Radiotherapy; Chemoradiotherapy; Tirapazamine; Classifier
ISSN (print) / ISBN 0167-8140
e-ISSN 1879-0887
Zeitschrift Radiotherapy and Oncology
Quellenangaben Band: 217, Heft: , Seiten: , Artikelnummer: 111433 Supplement: ,
Verlag Elsevier
Verlagsort Elsevier House, Brookvale Plaza, East Park Shannon, Co, Clare, 00000, Ireland
Begutachtungsstatus Peer reviewed
Institut(e) Translational Metabolic Oncology (IDC-TMO)
Förderungen Dieter Morszeck Foundation
National Center for Tumor Diseases (NCT) Heidelberg Radiation Oncology Program
Helmholtz Cross-Program Initiative Personalized Medicine (iMed) project on "Multi-Scale Integrative Biology of HNSCC"
German Cancer Consortium (DKTK)
Zentrum fur Personalisierte Medizin (ZPM-Network BW, Project MAX-PRO)